Zydus Cadila gets USFDA nod for drug to treat Psoriasis

The company's product is the generic version of Otezla tablets

94
USFDA
Picture: Pixabay

Last Updated on September 27, 2021 by The Health Master

NEW DELHI: Drug firm Zydus Cadila said it has received approval from the US health regulator to market Apremilast tablets, used to treat plaque psoriasis, in the American market.

The company’s US-based subsidiary Zydus Pharmaceuticals (USA) Inc has received final approval from the US Food and Drug Administration (USFDA) to market Apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg in the US market, Zydus Cadila said in a statement.

The company’s product is the generic version of Otezla tablets, which are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

The drug will be manufactured at the Zydus group’s formulation manufacturing facility at the special economic zone (SEZ), Ahmedabad, the drug firm noted.

The group now has 323 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.

Zydus Cadila gets USFDA nod for Antidepressant drug

Zydus Cadila gets tentative nod from USFDA for Brexpiprazole tablets

USFDA to review use of Blood Disorder Therapy in children

Aleor gets USFDA final approval for Metronidazole gel

Dr Reddy’s Labs gets USFDA nod for generic Librax capsules

Granules India gets Health Canada nod for drug for Arthritis pain

World Pharmacists Day: Salute to all Pharmacists – The Backbone of…

Gujarat is in the process of setting up a world class…

DCGI nod to BDR Pharma for drug to treat various infections

APTI asks PCI to fix pay scale for Pharmacy Teachers as…

AIOCD opposes installation of CCTV cameras in all Medical Stores

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner